A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection

Pediatric Pulmonology

Volumn 43, Issue 1, 2008, Pages 47-58

  Retsch Bogart, George Z ^a   Burns, Jane L ^b   Otto, Kelly L ^f   Liou, Theodore G ^c   McCoy, Karen ^d   Oermann, Christopher ^e   Gibson, Ronald L ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f NONE

Author keywords

Aztreonam lysine; Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; AZTREONAM LYSINE; BRONCHODILATING AGENT; LYSINE DERIVATIVE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HAND INJURY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEBULIZER; NOSE CONGESTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY FLOW RATES; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; PSEUDOMONAS INFECTIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 38349058630     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20736     Document Type: Article

References (26)

1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry Annual Data Report, 2000; Cystic Fibrosis Foundation, Patient Registry 2001.
2. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-161.
3. Hodson ME. Antibiotic treatment. Aerosol therapy. Chest 1988;94:156S-162S.
4. Wall MA, Terry AB, Eisenberg J, McNamara M, Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet 1983;1:1325.
5. Rose HD, Pendharker MB, Snider GL, Kory RC. Evaluation of sodium colistimethate aerosol in gram-negative infections of the respiratory tract. J Clin Pharmacol 1970;10:274-281.
6. Doring G, Conway SP, Heijerman HG, Hudson ME, Hoiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
7. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-765.
8. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 1995;39:34-39.
9. Rosenfeld M, Gibson R, McNamara S, Emerson J, McCoy KS, Shell R, Borowitz D, Konstan MW, Retsch-Bogart G, Wilmott RW, Burns JL, Vicini P, Montgomery AB, Ramsey B. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J Pediatr 2001;139:572-577.
10. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, Tanaka SK. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1999;43:2877-2880.
11. Burns J, Foster J. Aztreonam susceptibility of pathogens isolated from CF patients. Oct. 15-19, 2003; Anaheim, CA.
12. Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006;41:656-665.
13. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1987;6:393-397.
14. Scully BE, Ores CN, Prince AS, Neu HC. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Rev Infect Dis 1985;7:S669-S674.
15. Scully BE, Neu HC. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med 1985;78:251-261.
16. Dietzsch HJ, Gottschalk B, Heyne K, Leupold W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics 1975;55:96-100.
17. Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am J Respir Crit Care Med 2006;174:208-212.
18. Bucholski A, Keller M, Balcke A, Lintz F-C, Seemann S, Flitter WD, Hofmann T. In vitro Performance of eFlow™, an electronic inhaler for administration of a novel aztreonam formulation to CF patients. Pediatr Pulmonol Suppl. Volume 25; 2003. p A392, p 321.
19. Keller M, Stempfle P, Reul K, Waldner R, Lintz F-C, Opolski Sv, Menges G, Seemann S, Stapleton K. High Efficiency Pulmonary Drug Delivery of a Novel Formulation of Aztreonam by the eFlow. International Society for Aerosols in Medicine, 14th International Congress, June 14-18, 2003; Baltimore, MD.
20. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-1196.
21. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
22. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, Gore EJ, Redding GJ. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 1989;7:265-271.
23. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey BW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997;111:955-962.
24. AZACTAM® (aztreonam for injection) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2004.
25. Hodson ME, Gallagher CG, Go van JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664.
26. Murphy TD, Anbar RD, Lester LA, Nasr SZ, Nickerson B, VanDevanter DR, Colin AA. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004;38:314-320.